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Abstract
Although screening is effective in reducing incidence, mortality, and costs of treating colorectal 
cancer (CRC), it remains underutilized, in part due to limited insurance access. We used 
microsimulation to estimate the health and financial effects of insurance expansion and reduction 
scenarios in North Carolina (NC). We simulated the full lifetime of a simulated population of 
3,298,265 residents age-eligible for CRC screening (ages 50–75) during a 5-year period starting 
January 1, 2018, including polyp incidence and progression and CRC screening, diagnosis, 
treatment, and mortality. Insurance scenarios included: status quo, which in NC includes access to 
the Health Insurance Exchange (HIE) under the Affordable Care Act (ACA); no ACA; NC 
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Medicaid expansion, and Medicare-for-all. The insurance expansion scenarios would increase 
percent up-to-date with screening by 0.3 and 7.1 percentage points for Medicaid expansion and 
Medicare-for-all, respectively, while insurance reduction would reduce percent up-to-date by 1.1 
percentage points, compared to the status quo (51.7% up-to-date), at the end of the 5-year period. 
Throughout these individuals' lifetimes, this change in CRC screening/testing results in an 
estimated 498 CRC cases averted with Medicaid expansion and 6031 averted with Medicare-for-
all, and an additional 1782 cases if health insurance gains associated with ACA are lost. Estimated 
cost savings – balancing increased CRC screening/testing costs against decreased cancer treatment 
costs – are approximately $30M and $970M for Medicaid expansion and Medicare-for-all 
scenarios, respectively, compared to status quo. Insurance expansion is likely to improve CRC 
screening both overall and in underserved populations while saving money, with the largest 
savings realized by Medicare.
1. Introduction
Colorectal cancer (CRC) has the fourth highest incidence and is the second leading cause of 
cancer-related death in the United States (American Cancer Society, 2017). Given the 
prevalence of this disease, the economic burden associated with CRC is high and anticipated 
to increase (Mariotto et at, 2011). Fortunately, routine CRC screening – for which multiple 
modalities are recommended – is effective (U.S. Preventive Services Task Force et at, 2016). 
Two modalities are widely used. Of these, colonoscopy is more accurate (higher sensitivity 
and specificity) in detecting CRC and allows for immediate removal of any pre-cancerous 
polyps found, but includes the potential risks and costs associated with an invasive exam. 
Fecal testing, such as fecal immunochemical testing (FIT), can also detect CRC and can be 
completed at home or in a clinical office setting. However, it must be followed by a 
colonoscopy in the event of an abnormal result to confirm CRC and remove any polyps 
found. Screening is recommended for average-risk individuals 50–75 years of age – either a 
colonoscopy every ten years or fecal testing annually (U.S. Preventive Services Task Force 
et al., 2016).
Despite the ability to prevent most CRC, screening rates nationally remain relatively low, 
with approximately two-thirds (67.3%) of age-eligible individuals self-reporting being up-
to-date with recommendations in 2016 (Joseph et al., 2018). This rate falls below the 
Healthy People 2020 goal of 70.5% (Office of Disease Prevention and Health Promotion, 
2019), and well below the National Colorectal Cancer Roundtable's target of 80% by 2018 
(National Colorectal Cancer Roundtable, 2019). The gap between target and actual rates is 
likely even greater, however, as self-reported screening has been shown to overestimate up-
to-datedness (Pierannunzi et al., 2013) – by 12 to 13 percentage points in North Carolina 
(NC) (Hassmiller Lich et al., 2017).
There have been many efforts to improve CRC screening rates through implementation of 
single and multi-pronged evidence-based interventions (EBIs) (Sabatino et al., 2012; 
Dougherty et al., 2018; Davis et al., 2018). Substantial state-level financial investments have 
been made to improve screening rates in diverse subpopulations, including research-
supported interventions and technical assistance projects funded by the Centers for Disease 
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Control and Prevention (CDC) (Coughlin et al., 2006; Joseph et al., 2011). In a prior 
analysis, we found that investing $1–4 million on top of the cost of care in NC to target CRC 
screening non-compliance using current EBIs – without addressing access to care more 
broadly – would have limited effects on improving CRC screening at the population level 
(Hassmiller Lich et al., 2017).
Access to health insurance is an important barrier to CRC screening, as evidenced by the 
substantial gap in the probability of getting screened between those with and without 
insurance (National Center for Health Statistics, 2015). Among adults ages 50 to 64 years, 
those with private insurance were 2.5 times more likely to be screened for CRC compared to 
the uninsured in 2015 (National Center for Health Statistics, 2015). Low-income Medicaid 
enrollees, who are known to have relatively low screening rates, also have higher rates than 
the uninsured (Medicaid and CHIP Payment and Access Commission, 2016; Davis et al., 
2017). Improved access to insurance will likely reduce current barriers and disincentives to 
getting preventive care, but insurance expansion remains actively under debate at the state 
and national levels.
In this paper, we build on prior efforts to estimate the population-level impact of EBIs to 
estimate the impact of insurance expansion or reduction scenarios on CRC screening, 
incidence, mortality, and related costs (e.g., CRC screening and treatment) among NC 
residents age-eligible for screening. As before (Hassmiller Lich et al., 2017), we use 
microsimulation – a type of modeling that simulates individuals with diverse characteristics 
as they age and change over time, tracking both individual and population-level outcomes 
(Wheeler et al., 2018). Specifically, we use microsimulation to compare CRC outcomes and 
cost implications under five health insurance scenarios: status quo, which, in NC, reflects 
some increase in insurance when the Health Insurance Exchange (HIE) was implemented 
under the Affordable Care Act (ACA); reversal of the ACA; expansion of the state's 
Medicaid program; and two Medicare-for-all scenarios (with more and less conservative 
screening uptake). The results provide insight into how changing access to insurance 
coverage may help to narrow (or widen) the gap between established targets and current 
levels of screening, both overall and among subpopulations experiencing disparities.
2. Methods
We used an individual-based microsimulation model that integrates best available data to 
simulate lifetime CRC outcomes under each of the five insurance scenarios for the full 
population of 3,298,265 NC residents age-eligible for CRC screening over a five-year study 
period (January 1, 2018-December 31, 2022). Key model parameter values are reported in 
Table 1. This study was approved by the University of North Carolina Institutional Review 
Board.
2.1. Population simulated
We used a synthetic population, which is a realistic but not real population of simulated 
individuals whose characteristics are based on those of the state population at a single point 
in time. The simulated population was created using the Topologically Integrated 
Geographic Encoding and Referencing (TIGER), Summary File 3 (SF3), and American 
Lich et al. Page 3
Prev Med. Author manuscript; available in PMC 2020 March 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Community Survey Public Use Microdata Sample (PUMS) datasets from the U.S. Census 
Bureau from 2007 to 2011, to represent the NC population in 2009 (Wheaton et al., 2009; 
RTI International, 2019; The University of North Carolina at Chapel Hill, 2019). In this 
analysis, we restrict focus to the simulated individuals in the state who, if they did not die 
before January 1, 2018, would be age-eligible for screening at some time during the five-
year study period.
Time-invariant characteristics of simulated individuals are based on the synthetic population 
and include race, gender, and county of residence (we assume no migration for simplicity). 
Time-variant characteristics are changed within the simulation model and include age, 
income, insurance status, preferred routine screening modality, and polyp/cancer status. 
These characteristics may affect an individual's screening and/or cancer risk. Aging, non-
CRC mortality, initial insurance (i.e., in 2009), and status-quo screening are based on our 
previous work and described elsewhere (Hassmiller Lich et al., 2017).
For this analysis, we updated how we simulate individuals' income, insurance, and 
polyp/CRC status over time. To account for income change, each individual's income is 
updated from the 2009 simulated population value using multipliers based on U.S. Census 
Bureau data on per-capita income, stratified by race (white, black, other), sex (male, female), 
and age category (35–44, 45–54, 55–64, 65–74, 75+) (United States Census Bureau, 2019). 
From these data, we obtained multipliers and used them to convert each individual's income 
value in 2009 to his or her expected income value in each year thereafter. Because 2017 was 
the most recent year in which mean per-capita income was available at the time of this study, 
the annual rates of change beyond 2017 were obtained through extrapolation. Insurance, 
initially based on Census data, changes over simulated individuals' life course based on 
simple rules (Hassmiller Lich et al., 2017), which have been updated to reflect insurance 
scenarios and described in more detail below.
2.2. Polyp incidence and progression
Simulated individuals have a chance of developing one or more polyps during their lifetime. 
Polyps can grow from birth, with incidence rates changing across the life course (Lansdorp-
Vogelaar et al., 2009), and are characterized as small, medium, or large. All polyps start out 
small (<6 mm), but can transition to medium (6–9 mm) or large (≥10mm) over time 
(Subramanian et al., 2009). Although possible to detect, small polyps do not pose immediate 
risk of cancer. Medium and large polyps can transition into and across pre-clinical CRC 
stages, or become clinically relevant when diagnosed based on symptoms or through 
screening/testing. Each time-to-transition is modeled according to an exponential 
distribution, with the average number of years for a small polyp to transition to a medium 
polyp and for a medium polyp to transition to a large polyp set to 15 years and 5 years, 
respectively, based on prior research (Subramanian et al., 2009).
2.3. Status quo CRC screening and diagnostic testing
In the status quo scenario, all simulated individuals may receive routine CRC screening 
when they become age-eligible at 50 years of age, with some colonoscopies happening as 
early as 45 years of age; this matches observed variation in age at first screen in claims data 
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and accounts for differences in screening guidelines, such as an earlier recommended 
starting age for African Americans compared to other groups (Williams et al., 2016; Rex et 
al., 2017). Receipt and modality of screening/testing are simulated with randomness using 
predicted probabilities estimated from multi-variable statistical models that are a function of 
both individual characteristics (insurance, sex, race/ethnicity, county of residence, and 
distance between zip code centroid and nearest endoscopy facility) and characteristics of 
individuals' county of residence (population-adjusted number of medical generalists, 
percentage of residents below federal poverty level) (Hassmiller Lich et al., 2017). 
Individuals are considered up-to-date and not offered screening if they completed a 
colonoscopy within the past 10 years or a fecal test in the past 12 months. We do not 
simulate any other CRC screening tests, as they are observed infrequently, comprising <4% 
of all CRC tests in our underlying claims analysis (Wheeler et al., 2017). See Table 1 for 
assumptions about screen/test accuracy.
We simulate CRC screening for all individuals as soon as they become age-eligible, 
regardless of whether this occurred prior to or during the study period, to fully capture all 
screening, polyp identification/removal, and cancer outcomes in their full lifetimes. 
Predicted probabilities of screening estimated with the statistical models are adjusted over 
time to capture underlying temporal trends in clinical practice, norms, and other relevant 
patient-level factors (Hassmiller Lich et al., 2017). When polyp(s) are found during 
colonoscopy, we assume they are removed and analyzed, and assign costs for polypectomy 
and pathology. For those who screen by fecal test and have a positive (abnormal) result, they 
are offered a diagnostic colonoscopy, consistent with national guidelines (U.S. Preventive 
Services Task Force et al., 2016). Assuming imperfect follow-up, 85% of these individuals 
will receive diagnostic colonoscopies (Bogie & Sanduleanu, 2016). Individuals undergoing a 
colonoscopy have a small chance of bleeding or perforation, both of which are assumed to 
be treated (Lin et al., 2016).
2.4. CRC detection, treatment, and mortality
For individuals with pre-clinical CRC whose diagnostic test is inaccurately negative or those 
who do not have a diagnostic test, the cancerous polyp remains clinically undetected and 
continues to progress until it is diagnosed at some future point or the individual dies of 
causes other than CRC. We assume that all CRC is diagnosed before patients die from 
cancer. Patients who are diagnosed with CRC are treated, and associated costs (adjusted by 
stage and age) and survival (adjusted by stage, age, race, and sex) are tracked. CRC stage is 
based on the extent of malignancy, and modeled according to the definitions established by 
the American Joint Committee on Cancer (AJCC) (Edge & Compton, 2010). Mortality is 
determined as the minimum of their natural life expectancy (Arias, 2004) and cancer 
mortality risk (National Cancer Institute, 2019). Rates of transition to and between pre-
clinical CRC stages are calibrated using CRC incidence data from the NC Central Cancer 
Registry for the years 2008 to 2014 among individuals 37–92 years of age (NC State Center 
for Health Statistics, 2019).
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2.5. CRC screening, surveillance, and treatment costs
We estimated the costs of CRC-related preventive care and treatment for each insurance 
scenario from the perspective of individual payers. The total cost of screening/testing for 
each scenario includes the costs of routine screening by colonoscopy or fecal test, diagnostic 
colonoscopies in the event of abnormal fecal test results or polyps found on routine 
colonoscopy, surveillance examinations, the removal of polyps during colonoscopy, 
pathology, treatment for complications during colonoscopy, and cancer treatment. We 
identified the Current Procedural Terminology (CPT) codes for these procedures using the 
2018 NC Medicare Part B Fee Schedule (Centers for Medicare & Medicaid Services, 2018). 
We assigned the associated costs directly to the Medicare payer perspective, and then used 
these costs to estimate costs for other payers based on assumptions informed by expert 
opinion. Specifically, we assumed the costs for privately insured and Medicaid enrollees are, 
on average, three times the Medicare costs and 95% of Medicare costs, respectively. We 
assumed the costs for patients dually enrolled in Medicare/Medicaid are the same as for 
Medicaid alone. For the uninsured, we accounted for charity care cost estimates, set to 40% 
of Medicare reimbursement, which would be borne by the facility/provider that performs the 
screening or provides cancer treatment while the patient is uninsured. Costs assigned to 
cancer care, including treatment and surveillance, are based on prior research (Yabroff et al., 
2008; Zauber et al., 2007). We converted all costs to 2018 U.S. dollars, with future dollars 
discounted at a rate of 3% per year.
2.6. Model calibration
We calibrated model parameters to match two primary data points: 1) existing survey-based 
estimates of the percentage of age-eligible individuals up-to-date on CRC screening adjusted 
to correct for self-report bias (Joseph et al., 2018; Pierannunzi et al., 2013; Hassmiller Lich 
et al., 2017), and 2) the number of incident CRC cases, including the distribution of stage at 
diagnosis, from the NC Central Cancer Registry (NC State Center for Health Statistics, 
2019). See model documentation for more detail (The University of North Carolina at 
Chapel Hill, 2019).
2.7. Insurance scenarios
We estimate and compare the impact of five health insurance change scenarios, described in 
Table 2, on CRC screening and outcomes. Briefly, these scenarios are: status quo (ACA), no 
ACA, Medicaid expansion, conservative Medicare-for-all, and enhanced Medicare-for-all. 
For the status quo scenario, we update 2009 insurance based on NCspecific insurance data 
between 2013 and 2016 to capture insurance acquisition associated with the ACA. 
Specifically, we estimated the likelihood that each uninsured simulated individual would 
gain insurance in 2014 and 2015, with insurance gains based on individuals' household 
income, age, gender, marital status, and race. Insurance gains level out between 2015 and 
2016, so no further increases in insurance are simulated thereafter due to ACA. In the 
conservative Medicare-for-all scenario, we assume people will screen at rates consistent with 
current screening among others like themselves (i.e., this is based on income/Medicaid 
eligibility). In the more optimistic Medicare-for-all scenario, we assume screening rates for 
all individuals level out at current screening rates among individuals with higher incomes.
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2.8. Simulation outcomes and analyses
The simulation model was programmed in AnyLogic (version 7.3.6). To ensure an 
individual's life course is otherwise identical across insurance scenarios, an application of 
common random numbers is used (Cornejo et al., 2014). We track percent up-to-date overall 
and within subgroups after the five-year study period (i.e., on December 31, 2022). We also 
track years up-to-date, CRC incidence (overall and by AJCC stage), CRC mortality, life-
years, and CRC costs overall and by payer over the full lifetime of the simulated population. 
We present results for the status quo scenario, and for other insurance change scenarios 
compared to this scenario. Five replications were run for this analysis, and average outcomes 
are presented along with uncertainty intervals, defined here as the replication minimum and 
maximum, for primary simulation outcomes (percent up-to-date after five years and total 
CRC cases and total life-years within simulated individuals' lifetimes in each scenario). To 
assess robustness in estimated relative differences across scenarios, we rank order scenarios 
based on each primary outcome, within each replication, and average scenario rankings 
across replications.
Given the large simulated population size, we needed few replications to obtain precise 
simulation estimates. The use of common random numbers also contributes to the consistent 
results across replications and the quick stabilization of cross-replication statistics (Cornejo 
et al., 2014). Adding the fifth replication was sufficient to reach our stopping condition – 
when adding another replication changed the cross-replication average for each primary 
simulated outcome by <1%. All statistical analyses were conducted using R Statistical 
Software (version 3.3.3).
3. Results
Table 3 presents the demographic and insurance mix in the simulated NC population age-
eligible for CRC screening (50–75) on December 31, 2013 (just before ACA was 
implemented), on December 31, 2014 (after one year of ACA) and on December 31, 2017 
(just before our study period). As expected, the most noteworthy differences in these 
snapshots include a decrease in the percent uninsured as a result of insurance reform and 
aging of the population, occurring in NC much like many other states. We project that a total 
of 3,298,265 individuals who would have been alive on December 31, 2017 will be between 
50 and 75 years of age at some point during the five-year study period.
Table 4 presents the difference in the percent of age-eligible individuals up-to-date with 
CRC screening/testing in each insurance scenario as compared to ACA at the end of the 
study period – both overall and by sociodemographic characteristics. On December 31, 
2022, we estimate that 51.7% of the population would be up-to-date with screening under 
ACA. With no ACA, the percent up-to-date would be 1.1 percentage points lower. In 
contrast, the insurance expansion scenarios increase the screened population compared to 
ACA: 0.3 percentage points with Medicaid expansion, 7.1 percentage points for conservative 
Medicare-for-all, and 8.6 percentage points for enhanced Medicare-for-all. The magnitude of 
these differences varies by demographic subgroups. For example, among Hispanics, there is 
an expected increase in up-to-datedness of 1.3 percentage points for Medicaid expansion, 
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11.6 percentage points for conservative Medicare-for-all, and 14.5 percentage points for 
enhanced Medicare-for-all, relative to ACA (44.7% up-to-date).
Fig. 1 is comprised of a panel of maps indicating the percent of age-eligible residents in each 
zip code up-to-date with CRC screening/testing at two time points - December 31, 2017 
(ACA) and December 31, 2022 (under each insurance change scenario). No zip codes would 
reach 70.5% up-to-date targets under any scenario; the zip code with the highest percent up-
to-date under enhanced Medicare-for-all is 67.7%.
Table 5 presents the difference in lifetime CRC diagnoses and deaths for each scenario 
compared to ACA between January 1, 2018 when insurance change scenarios were 
implemented and 2072 when the full simulated population is deceased. During this period, a 
total of 153,806 incident CRC cases will be diagnosed, of which 33,754 will be Stage 1, 
32,603 will be Stage 2, 45,201 will be Stage 3, and 42,248 will be Stage 4. Compared to 
ACA, the number of CRC cases averted by insurance expansion would be 498 for Medicaid 
expansion, 6031 for conservative Medicare-for-all, and 7602 for enhanced Medicare-for-all. 
The no ACA scenario, however, would result in 1782 additional CRC cases relative to ACA. 
CRC-attributable deaths follow a similar pattern, as shown in Table 5. In addition, insurance 
expansion is expected to increase both total years up-to-date with CRC screening and total 
years of life among the simulated population, while insurance reduction would have the 
opposite effect, compared to ACA (see Supplemental Table 1). For example, the population 
will gain 5431 life-years with Medicaid expansion, 56,248 life-years with conservative 
Medicare-for all, and 68,399 life-years with enhanced Medicare-for-all, but lose 14,531 life-
years if the ACA is reversed, across the individuals' cumulative lifespans, relative to the 
ACA. In terms of the total number of years up-to-date with CRC screening compared to the 
ACA, Medicaid expansion will result in 92,887 more years, conservative Medicare-for-all 
will result in 1,452,876 more years, and enhanced Medicare-for-all will result in 2,178,523 
more years, while the no ACA scenario is expected to have 384,842 fewer years up-to-date.
Fig. 2 presents cumulative CRC cost savings for each insurance change scenario compared 
to ACA in 2018 U.S. dollars, discounted at 3% per year. Compared to ACA, the no ACA 
scenario is cost saving through 2054, when marginal costs associated with worse CRC 
outcomes offset earlier gains from reduced screening/testing. This scenario is associated 
with a cumulative discounted cost increase of $3.2 million. In contrast, cumulative 
discounted costs under the Medicaid expansion scenario are initially higher than the ACA 
scenario, breaking even in 2025 and ultimately saving an additional $28.2 million. Both 
Medicare-for-all scenarios are immediately cost saving, with cumulative discounted cost 
savings reaching $970.9 and $1037.7 million, respectively, for the conservative and 
enhanced scenarios compared to ACA.
Fig. 3 presents cumulative CRC cost savings for each payer under the no ACA and Medicaid 
expansion scenarios compared to the ACA scenario in 2018 U.S. dollars, discounted at 3% 
per year. We do not show payer-specific costs for the Medicare-for-all scenarios, as all costs 
will be shifted to Medicare under these scenarios. From the perspective of private insurers, 
the Medicaid expansion scenario would be slightly cost saving (compared to the ACA), 
whereas the removal of ACA would save approximately $200 million by 2030. From the 
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Medicaid perspective, removing the ACA would save about $8 million in CRC-related costs 
and expanding Medicaid would cost an additional $50 million by 2030, compared to ACA. 
In the case of dual Medicaid/Medicare enrollees, both removal of ACA and Medicaid 
expansion would cost more, compared to ACA. The removal of ACA would be less 
expensive, increasing cumulative discounted costs by approximately $5 million while 
Medicaid expansion would increase costs by approximately $85 million (though with a 
delay). Medicare would quickly reap cost savings from Medicaid expansion, increasing to 
about $100 million in 2055, while removal of ACA would result in an approximate $100 
million increase in cumulative costs by the same time, both compared to ACA. Medicaid 
expansion would save nearly $60 million in uncompensated care by 2035, while removal of 
ACA would increase cumulative costs by nearly $120 million by 2034, compared to the 
ACA.
We present uncertainty intervals (the minimum and maximum values across replications) for 
primary simulation outcomes in Tables 4 and 5 and Supplemental Table 1. The uncertainty 
intervals for percent up-to-date (Table 4) are fairly narrow, though the corresponding 
intervals for CRC diagnoses and life-years are wider. While these intervals overlap across 
scenarios, analysis of scenario rankings within each replication indicate our conclusions 
about scenario dominance are robust to uncertainty. This is particularly true for scenario 
rankings based on percent up-to-date; scenario rankings across every replication were the 
same as the rankings based on average cross-replication results presented in Table 4. While 
there was some heterogeneity in the relative impact of enhanced insurance access (and thus 
screening) on the number of CRC cases, the rank orderings in terms of life-years gained 
were more robust across scenarios. This indicates that increased insurance (and thus 
screening) can result in more CRC diagnoses, but typically at earlier stages and producing a 
net increase in life-years.
4. Discussion
Our findings suggest that, at the population-level, insurance expansion will improve CRC 
screening, reduce the number of incident CRC cases, shift the burden of CRC cases from 
later to earlier stages at diagnosis, reduce CRC-attributable mortality, and add years to 
people's lives – at a cost savings across payers. If NC expands its Medicaid program, which 
would add short-term costs associated with screening, annual costs would be expected to 
decline within seven years, saving more than $28 million for this population of all NC 
residents age-eligible for CRC screening over the five-year study period. Nearly 500 fewer 
people in this population will develop CRC, saving more than 200 lives and adding more 
than 5000 years of life. These numbers increase by more than a factor of 12 for the 
conservative scenario and 15–16 for the enhanced scenario if insurance expansion via 
Medicare is extended to all. Cost savings increase even more – by a factor of 34–36, 
depending on whether the more conservative or enhanced Medicare-for-all scenario is 
considered. That said, the expected impact varies across payers, with some benefitting more 
than others. For example, if Medicaid is expanded (on top of ACA), the costs to Medicaid 
will rise in the short term whereas Medicare costs and the cost of uncompensated care will 
decrease. Some of these cost savings could be shifted to offset the increased burden on the 
state to expand its Medicaid program, increasing the likelihood that insurance access will be 
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expanded to more low-income individuals. Medicare-for-all scenarios demonstrate the 
potentially sizeable cost savings attributable to both enhanced prevention and the impact of 
lower rates associated with volume-based purchasing.
As much as insurance expansion improves health and saves money, this analysis also 
highlights the reductions in insurance access that would stem from the reversal of ACA and 
the corresponding negative impact on health and cost outcomes. Among this population 
simulated, reversal of ACA would lead to 1782 additional CRC diagnoses, 791 more deaths, 
and 14,531 fewer years of life, compared to the status quo. If we consider that there were an 
estimated 3,298,265 individuals exposed to CRC screening in the study period, this implies 
increased CRC incidence and mortality rates of 54 and 24 per 100,000 population, 
respectively.
Despite the sizable improvements in health and cost outcomes associated with the insurance 
expansion scenarios for most payers, none of these scenarios are capable of increasing 
screening to the 70.5% (Office of Disease Prevention and Health Promotion, 2019) or 80% 
(National Colorectal Cancer Roundtable, 2019) targets by 2022. Indeed, these targets are not 
reached in a single zip code across NC. Furthermore, insurance expansion by itself is not 
able to eliminate CRC screening disparities by gender, race/ethnicity, or geography. 
Projections in Table 4 and Fig. 1 could inform more attainable state and national screening 
targets. Considering both these results and our previous analysis of EBIs in NC (Hassmiller 
Lich et al., 2017), it is clear that a combination of insurance expansion and multiple EBIs 
will be needed to reach established targets.
While it is difficult to reach current national screening targets of 70.5% and 80%, research 
has shown that we are getting closer to these targets, especially among subpopulations or 
within individual clinics or facilities. For instance, our microsimulation in Oregon found that 
a mailed FIT plus patient navigation intervention has the potential to increase the percent of 
Oregon residents enrolled in Medicaid coordinated care organizations by 20.2 percentage 
points (to 70.3%) after five years (Davis et al., 2019). The difficulty lies in reaching these 
targets at the population level, either state-wide or country-wide. While it is important to 
note, though, that screening programs and national targets differ greatly from country to 
country (Young et al., 2019; Navarro et al., 2017), international comparisons indicate that 
the 80% target has not been reached at the country level, although substantial progress has – 
and thus can – be made toward the 70.5% target when EBIs and broad access to insurance 
are combined (Young et al., 2019; Navarro et al., 2017).
Like all microsimulation initiatives, this study has limitations. While such models can be 
used to integrate fragmented datasets, they require structural and numeric (parameter value) 
assumptions. We attempted to make all modeling assumptions transparent here and in the 
model documentation. However, as the context of CRC care evolves, these assumptions will 
need to be updated and conclusions might change. For example, if the cost of CRC treatment 
decreases (Mennini et al., 2019) while the cost of screening remains fixed, cost savings 
associated with insurance expansion may shift. This is not likely to be the case, though, as 
cancer treatment costs have risen dramatically in the recent past. While both polyp size and 
histology affect the progression to CRC and CRC detection, our natural history model 
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currently only distinguishes between different sized polyps (though it is well-calibrated to 
historical screening and CRC cancer registry data). As another limitation, we focused on 
outcomes among a five-year population of age-eligible individuals. Until more up-to-date 
simulated populations are available, we feel this decision offers a balance between 
projecting outcomes of interest (e.g., impact on percent up-to-date, ability to meet 
established targets in the future) with concerns about the generalizability of the simulated 
population far beyond 2009. Lastly, we make a simplifying assumption of no migration. 
Given that the rates of movement into and out of the state are approximately balanced 
(Tippett, 2018), and with the older adult population (the focus of this study) less transient in 
this state (Rosenthal, 2017), we believe the impact on our results to be minimal. Future work 
to update the synthetic population, to account for migration patterns, to further develop the 
natural history model to account for polyp histology, to simulate combined insurance 
expansion and EBI scenarios, and to consider the impact of parameter uncertainty on 
conclusions is needed.
5. Conclusions
Our state-level microsimulation results suggest that insurance expansion is a powerful 
approach to increasing CRC screening and improving CRC-related health outcomes while 
reducing costs of care. In NC, the ACA has increased the percent of the population up-to-
date with CRC screening/testing by 1.1 percentage points – more than the multimillion 
dollar investments designed to improve screening simulated in prior work (Hassmiller Lich 
et al., 2017). Medicaid expansion would increase this by another 0.3 percentage points 
(more on par with these EBIs). Microsimulation models can be used as illustrated here to 
support decision makers in choosing between approaches, or in better understanding what it 
will take to reach established targets, efficiently.
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Fig. 1. 
Maps of percent up-to-date with CRC screening/testing by zip code in North Carolina under 
the ACA (December 31, 2017 before the study period and December 31, 2022 at the end of 
the study period) and other insurance change scenarios (December 31, 2022 at the end of the 
study period).
Lich et al. Page 16
Prev Med. Author manuscript; available in PMC 2020 March 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Cumulative cost savings across payers discounted at 3% per year, comparing each insurance 
change scenario to ACA.
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Fig. 3. 
Cumulative cost savings discounted at 3% per year, by payer (insurance type) for the no 
ACA (heavy black line) and Medicaid expansion (heavy gray line) scenarios compared to 
the ACA scenario.
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